The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance
- 1 May 2019
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 131, 86-89
Abstract
No abstract availableKeywords
Funding Information
- Princess Margaret Cancer Foundation
This publication has 9 references indexed in Scilit:
- Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to OsimertinibJAMA Oncology, 2018
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCJournal of Thoracic Oncology, 2018
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA ProfilingCancer Discovery, 2017
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsNature Communications, 2016
- Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patientsBritish Journal of Cancer, 2016
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyClinical Cancer Research, 2015
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceJournal of Thoracic Oncology, 2015
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerCancer Discovery, 2014